Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology
Daniel E. Spratt, Sandy Srinivas, Nabil Adra, Bilawal Ahmed, Yi An, Rhonda L. Bitting, Brian F. Chapin, Heather H. Cheng, Steve Y. Cho, Anthony V. D’Amico, Neil Desai, Tanya B. Dorff, James A. Eastham, Thomas A. Farrington, Xin Gao, Shilpa Gupta, Joseph E. Ippolito, R. Jeffrey Karnes, Amar U. Kishan, Michael Kuettel, Joshua M. Lang, Daniel Lee, Tamara L. Lotan, Andrew J. McDonald, Todd M. Morgan, Rodrigo Rodrigues Pessoa, Soroush Rais‐Bahrami, Mack Roach, Tyler P. Robin, Stan Rosenfeld, Kristen R. Scarpato, Ahmad Shabsigh, Russell Z. Szmulewitz, Benjamin A. Teply, Jonathan D. Tward, Richard K. Valicenti, David James VanderWeele, J.K. Wong, E Kovách, Deborah A. Freedman-Cass
Abstract
The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions for patients with prostate cancer across the disease spectrum. The Guidelines sections included in this article focus on metastatic castration-sensitive prostate cancer (mCSPC), nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC). For patients with mCSPC, disease characteristics, such as whether metastases arose synchronously or metachronously and the degree of metastatic burden, impact therapy decisions, including how much treatment intensification is appropriate and when prostate-directed and/or metastasis-directed therapy should be considered. In the mCRPC setting, androgen deprivation therapy is continued with the sequential or concurrent addition of certain androgen receptor pathway inhibitors, chemotherapies, immunotherapies, radiopharmaceuticals, and/or targeted therapies. The NCCN Prostate Cancer Panel emphasizes a shared decision-making approach in all disease settings based on patient preferences, prior treatment exposures, biomarkers, the extent and location of metastases, symptoms, and potential side effects.